2014
Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate. JAMA Internal Medicine 2014, 174: 721-729. PMID: 24687044, PMCID: PMC4074594, DOI: 10.1001/jamainternmed.2014.601.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCD4 lymphocyte countViral suppressionHIV viral suppressionLymphocyte countObserved therapyRNA levelsBaseline HIV-1 RNA levelsMean HIV-1 RNA levelHuman immunodeficiency virus (HIV) treatmentHuman immunodeficiency virus managementHIV treatment outcomesRetrospective cohort studyAntiretroviral therapy regimensHIV-1 RNAPsychiatric disorder severityLogistic regression modelsCommunity-based resourcesDuration of incarcerationRace/ethnicityART regimenContinuous ARTPrescribed pharmacotherapyAntiretroviral therapyART regimens
2007
Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners
Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyImmunological outcomesHIV-1 RNA levelsCells/mulActive antiretroviral therapyEffective antiretroviral therapyRetrospective cohort studyDuration of therapyKaplan-Meier curvesHIV-1 RNAProportion of subjectsHAART strategyTriple NRTICohort studyCopies/Incarceration periodsTreatment strategiesHigh prevalenceMean changeStudy groupNRTIsHIVTherapyRNA levelsLaboratory data
2004
Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community
Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community. Clinical Infectious Diseases 2004, 38: 1754-1760. PMID: 15227623, DOI: 10.1086/421392.Peer-Reviewed Original ResearchMeSH KeywordsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesHIV InfectionsHIV-1HumansPrisonersPrisonsRetrospective StudiesViral LoadConceptsMean CD4 lymphocyte countCD4 lymphocyte countAntiretroviral therapyLymphocyte countCopies/Sustained benefitHuman immunodeficiency virus type 1 RNA levelsActive antiretroviral therapyRetrospective cohort studyLog10 copies/Mu LHAART useCohort studyHIV diseaseLymphocyte responsesPoor outcomeIncarcerated patientsRNA levelsLaboratory dataTherapyCorrectional settingsIncarceration periodsOutcomesPeriod of incarcerationCount